At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VVOS Vivos Therapeutics
Post-Mkt 04-08 16:36:10 EDT
1.20
-0.04
-3.23%
盘后1.20
+0.000.00%
16:34 EDT
High1.29Low1.18Vol112.88K
Open1.29D1 Closing1.24Amplitude8.87%
Mkt Cap14.19MTradable Cap9.08MTotal Shares11.82M
T/O138.25KT/O Rate1.49%Tradable Shares7.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
GlobeNewswire  ·  04-07 20:45
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday
Benzinga_recent_news  ·  04-06 13:33
Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday
Vivos Therapeutics Completes Private Placement to Bolster Liquidity
TIPRANKS  ·  04-04
Vivos Therapeutics Completes Private Placement to Bolster Liquidity
Vivos Therapeutics raises $2.3 million in private placement with Seneca affiliate
Reuters  ·  04-04
Vivos Therapeutics raises $2.3 million in private placement with Seneca affiliate
Why Did Vivos Therapeutics (VVOS) Stock Jump Over 21% After Hours
Benzinga_recent_news  ·  04-03
Why Did Vivos Therapeutics (VVOS) Stock Jump Over 21% After Hours
Major Investor Quietly Ramps Up Stake in Vivos Therapeutics
TIPRANKS  ·  04-03
Major Investor Quietly Ramps Up Stake in Vivos Therapeutics
Michael C. Skaff reports $1.8 million Vivos Therapeutics common share acquisition
Reuters  ·  04-03
Michael C. Skaff reports $1.8 million Vivos Therapeutics common share acquisition
Vivos Therapeutics Delays Annual Filing Amid Expansion
TIPRANKS  ·  04-01
Vivos Therapeutics Delays Annual Filing Amid Expansion
Vivos Therapeutics delays filing annual report, cites Sleep Center of Nevada acquisition review
Reuters  ·  04-01
Vivos Therapeutics delays filing annual report, cites Sleep Center of Nevada acquisition review
Vivos Therapeutics Files for Non-Timely 10-K - SEC Filing
THOMSON REUTERS  ·  04-01
Vivos Therapeutics Files for Non-Timely 10-K - SEC Filing
Vivos Therapeutics: Anticipates Its REV Increased by Over 15% for Year Ended Dec 31, 2025
THOMSON REUTERS  ·  04-01
Vivos Therapeutics: Anticipates Its REV Increased by Over 15% for Year Ended Dec 31, 2025
Vivos Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Reuters  ·  03-28
Vivos Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Vivos Therapeutics Inc - Expects to Become Cash Flow Positive During Fiscal Year 2026
THOMSON REUTERS  ·  03-26
Vivos Therapeutics Inc - Expects to Become Cash Flow Positive During Fiscal Year 2026
Vivos Therapeutics Inc - Announces Cost Reduction Initiatives Including Reduction in Force and Vendor Changes
THOMSON REUTERS  ·  03-26
Vivos Therapeutics Inc - Announces Cost Reduction Initiatives Including Reduction in Force and Vendor Changes
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
GlobeNewswire  ·  03-26
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
Clinical study links narrow dental arches and high palates to obstructive sleep apnea severity, Vivos says
Reuters  ·  03-19
Clinical study links narrow dental arches and high palates to obstructive sleep apnea severity, Vivos says
BRIEF-Recent Study Confirms Fundamental Correlation Between Severity Of Obstructive Sleep Apnea And Oral Anatomy
Reuters  ·  03-17
BRIEF-Recent Study Confirms Fundamental Correlation Between Severity Of Obstructive Sleep Apnea And Oral Anatomy
Clinical study links narrower intermolar distance and higher palatal height to obstructive sleep apnea severity
Reuters  ·  03-17
Clinical study links narrower intermolar distance and higher palatal height to obstructive sleep apnea severity
Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
THOMSON REUTERS  ·  03-17
Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
Vivos Therapeutics files to sell 3.96M shares of common stock for holders
TIPRANKS  ·  02-17
Vivos Therapeutics files to sell 3.96M shares of common stock for holders
No data available

Introduction

Company Name.
Vivos Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.
Issue price:
--